Market Closed -
Japan Exchange
01:30:00 2024-12-13 am EST
5-day change
1st Jan Change
4,980.00 JPY
-0.30%
+0.10%
-3.11%
Noevir : Results for Fiscal 2024
November 14, 2024 at 08:37 pm EST
Noevir Holdings Co., Ltd.
Fiscal 2024
(October 1, 2023 - September 30, 2024)
November 15, 2024
Noevir Holdings Co., Ltd.
Ikkou Yoshida, Managing Director
Copyright © 2024 Noevir Holdings Co., Ltd. All Rights Reserved.
Company Overview
Noevir Holdings Co., Ltd. Tokyo Stock Exchange, Prime Market Ticker: 4928
Date of Establishment
March 22, 2011 (Noevir Co., Ltd. was founded in April 1964.)
Paid-in Capital
¥7,319 million
Consolidated Subsidiaries
13 subsidiaries (6 domestic / 7 international)
Employees
1,369 (Consolidated) (As of September 30, 2024)
Number of Shareholders
20,619 (As of September 30, 2024)
Outstanding Shares
34,156 thousand shares
Market Capitalization
¥170.612 billion (November 14, 2024 @ ¥4,995)
Line of Business
Cosmetics
Pharmaceuticals & Health Food
Copyright © 2024 Noevir Holdings Co., Ltd. All Rights Reserved.
Apparel
business Aviation- related business
Other
1
1. Results for Fiscal 2024
2. Fiscal 2024 Segment-based Highlights
3. Medium- to Long-term Strategy
4. Forecasts and Initiatives for Fiscal 2025
Copyright © 2024 Noevir Holdings Co., Ltd. All Rights Reserved.
2
Fiscal 2024 Consolidated Results Summary
Sales and profit increased for three consecutive periods
Achieved record-high net income attributable to owners of the parent
Fiscal 2024
Year-on-year
Planned Company
change
target
(vs. forecast target)
Net sales
63.8 billion yen
+2.0％
+1.3％
Operating income
11.4 billion yen
+3.6％
+2.0％
Operating income margin
17.9％
+0.3pt
+0.1pt
➢ Factor increasing sales and profits
Operating income margin
Self-selection cosmetics performed strongly
17.9％
Copyright © 2024 Noevir Holdings Co., Ltd. All Rights Reserved.
3
Fiscal 2024 Highlights
Net sales 63.8 billion yen (+2.0% year-on-year), operating income 11.4 billion yen (+3.6%),
ordinary income 11.5 billion yen (+2.6%), net income attributable to owners of the parent 7.9 billion yen (+3.9%)
Year ended September
Year ended September
Year-on-year change
Earning forecast
30, 2024
30, 2023
Millions of yen
Millions of yen
Millions of yen
％
Millions of yen
％
Net sales
63,823
62,552
1,270
2.0
63,000
1.3
Cost of sales
20,666
19,988
678
3.4
Gross profit
43,156
42,564
591
1.4
SG&A
31,733
31,540
193
0.6
Operating income
11,423
11,024
398
3.6
11,200
2.0
Non-operating income (expenses)
171
271
(100)
(36.9)
Ordinary income
11,594
11,295
298
2.6
11,400
1.7
Extraordinary income (losses)
24
2
21
854.8
Income before income taxes
11,619
11,298
320
2.8
Income taxes
3,648
3,625
23
0.7
Net income attributable to owners of the parent
7,970
7,673
296
3.9
7,800
2.2
Cost of sales ratio (%)
32.4
32.0
ー
0.4pt
ー
ー
Operating income margin (%)
17.9
17.6
ー
0.3pt
17.8
0.1pt
Ordinary income margin (%)
18.2
18.1
ー
0.1pt
18.1
0.1pt
Net income attributable to owners of the parent margin
12.5
12.3
ー
0.2pt
12.4
0.1pt
SG&A ratio (%)
49.7
50.4
ー
(0.7pt)
ー
ー
Copyright © 2024 Noevir Holdings Co., Ltd. All Rights Reserved.
4
Net Sales and Operating Income
(Millions of yen)
Net sales
Operating income
59,252
61,143
62,552
63,823
57,828
54,473
51,841
51,272
49,387
51,180
11,423
7,588
7,706
9,986
11,343
11,992
8,060
8,557
10,115
11,024
FY2015
FY2016
FY2017
FY2018
FY2019
FY2020
FY2021
FY2022
FY2023
FY2024
Sales and profit increased for three consecutive periods
Copyright © 2024 Noevir Holdings Co., Ltd. All Rights Reserved.
5
Operating Income Margin
18.3%
17.6%
16.7%
15.5%
16.5%
15.4%
15.1%
FY2015
FY2016
FY2017
FY2018
FY2019
FY2020
FY2021
FY2022
FY2023
FY2024
Continued to maintain a high operating income margin in FY2024
Copyright © 2024 Noevir Holdings Co., Ltd. All Rights Reserved.
6
Fiscal 2024 Reasons for Change in Operating Income
+591
-71
-82
-40
11,0240,115
Increasein gross profit
salestodue increase
Increasein personnel expenses
Increasein A&P
Increasein sundry expenses
FY2023
Increase in operating income of 398 million yen
Copyright © 2024 Noevir Holdings Co., Ltd. All Rights Reserved.
(Millions of yen)
Factors increasing profit
Factors decreasing profit
11,0241,423
FY2024
7
Monthly Net Sales in the Cosmetics Segment Year on Year
Fiscal 2024
2022
2023
2024
Oct.
Nov. Dec. Jan. Feb. Mar. Apr. May
Jun. Jul. Aug. Sep. Oct. Nov. Dec. Jan. Feb. Mar. Apr. May Jun. Jul. Aug. Sep.
Copyright © 2024 Noevir Holdings Co., Ltd. All Rights Reserved.
8
Return on Equity
15.0%
8.9 ％ 9.2%
FY2015
FY2016
FY2017
FY2018
FY2019
FY2020
FY2021
FY2022
FY2023
FY2024
Achieved stable management efficiency and reached a record high
Copyright © 2024 Noevir Holdings Co., Ltd. All Rights Reserved.
9
Attachments
Original document
Permalink
Disclaimer
Noevir Holdings Co. Ltd. published this content on November 15, 2024 , and is solely responsible for the information contained herein. Distributed by Public, unedited and unaltered, on November 15, 2024 at 01:37:32.037 .
Noevir Holdings Co., Ltd. Provides Consolidated Earnings Guidance for the Fiscal Year Ending September 30, 2025
Nov. 08
CI
Noevir Holdings Co., Ltd. Provides Consolidated Earnings Guidance for the Fiscal Year Ending September 30, 2024
Nov. 07
CI
Noevir Holdings Co., Ltd. Provides Consolidated Earnings Guidance for the Fiscal Year Ending September 30, 2024
23-08-07
CI
Noevir Holdings Co., Ltd. Reports Earnings Results for the Half Year Ended March 31, 2023
23-05-10
CI
Noevir Holdings Co., Ltd. Provides Consolidated Earnings Guidance for the Fiscal Year Ending September 30, 2023
23-05-10
CI
Noevir Holdings Co., Ltd. Provides Consolidated Earnings Guidance for the Six Months Ending March 2023 and for the Fiscal Year Ending September 30, 2023
23-02-07
CI
Noevir Holdings Co., Ltd. Provides Consolidated Earnings Guidance for the Six Months Ending March 2023 and for the Fiscal Year Ending September 30, 2023
22-11-10
CI
Noevir Holdings Co., Ltd. Provides Consolidated Earnings Guidance for the Period Ending September 2022
22-08-04
CI
Noevir Holdings Co., Ltd. Provides Consolidated Earnings Guidance for the Period Ending September 2022
22-05-11
CI
Noevir Holdings Co., Ltd. Provides Earnings Guidance for the Six Months Ending March 2022 and for the Year Ending September 2022
22-02-08
CI
FACTBOX-Japanese companies opening COVID-19 vaccination sites amid slow national rollout
21-06-04
RE
An unknown buyer acquired a 12.9% stake in Noevir Holdings Co., Ltd. from Takashi Okura.
20-08-02
CI
Noevir Holdings Co., Ltd. Announces Consolidated Earnings Results for the Nine Months Ended June 30, 2019; Provides Earnings Guidance for the Fiscal Year Ending September 30, 2019
19-08-13
CI
Noevir Holdings Co., Ltd. Announces Unaudited Consolidated Earnings Results for the First Quarter Ended December 31, 2018; Provides Earnings Forecast for the Half Year of the Fiscal Year Ending Sept. 30, 2019; Provides Earnings Forecast for the Full Year of the Fiscal Year Ending Sept. 30, 2019; Provides Dividend Forecast for the Fourth Quarter of Fiscal Year Ending Sept. 30, 2019
19-02-11
CI
Noevir Holdings Co., Ltd. Announces Consolidated Earnings Results for the Year Ended September 30, 2018; Provides Earnings Guidance for the Half Year and Year Ending September 30, 2019
18-11-19
CI
Noevir Holdings Co., Ltd. Provides Dividend Guidance for the Year Ending September 30, 2018; Announces Consolidated Earnings Results for the Nine Months Ended June 30, 2018; Provides Consolidated Earnings Guidance for the Fiscal Year Ending September 30, 2018
18-08-12
CI
Noevir Holdings Co., Ltd.(TSE:4928) added to FTSE All-World Index
18-03-19
CI
Noevir Holdings Co., Ltd.(TSE:4928) added to FTSE All-World Index
18-03-19
CI
Noevir Holdings Co., Ltd. Announces Unaudited Earnings Results for the Three Months Ended December 31, 2017; Provides Earnings Guidance for the Half Year and Full Year for the Fiscal Year Ended September 30, 2018
18-01-31
CI
Tranche Update on Noevir Holdings Co., Ltd.'s Equity Buyback Plan announced on November 7, 2017.
17-11-08
CI
Noevir Holdings Co., Ltd.'s Equity Buyback announced on November 7, 2017 has expired with 1,295,000 shares for ¥9,971.5 million.
17-11-08
CI
Noevir Holdings Co., Ltd. announces an Equity Buyback for 1,500,000 shares, representing 4.23% for ¥11,000 million.
17-11-07
CI
Noevir Holdings Co., Ltd. authorizes a Buyback Plan.
17-11-06
CI
Noevir Holdings Co., Ltd. Announces Consolidated Earnings Results for the Full Year Ended September 30, 2017; Provides Consolidated Earnings Guidance for the First Half and Full Year Ending September 30, 2018; Announces Year-End Dividend for the Year Ended September 30, 2017, Payable on December 8, 2017; Provides Dividend Guidance for the Year Ending September 30, 2018
17-11-06
CI
Noevir Holdings Co., Ltd. Reports Consolidated Earnings Results for the Nine Months Ended June 30, 2017; Provides Consolidated Earnings Guidance for the Full Year Ending September 30, 2017
17-07-31
CI
Duration Auto. 2 months 3 months 6 months 9 months 1 year 2 years 5 years 10 years Max.
Period Day Week
4928: Dynamic Chart
Noevir Holdings Co., Ltd. is a Japan-based company engaged in the manufacture and sale of cosmetics, toiletries, pharmaceuticals and foods, as well as the purchase and sale of cosmetic products. The Company operates in three business segments. The Cosmetics segment is engaged in the manufacture and sale of cosmetics and toiletries, as well as the purchase and sale of cosmetic products. The Pharmaceuticals and Foods segment is engaged in the manufacture and sale of general drugs and foods. The Others segment is engaged in the purchase and sale of apparels, body fashion, aircrafts and vessels, as well as air transportation business.
More about the company
Last Close Price
4,980.00 JPY
Average target price
5,320.00 JPY
Spread / Average Target
+6.83%
Consensus
+951% of historical
More than 20 years
Our Experts
OUR EXPERTS ARE HERE FOR YOU
Monday - Friday 9am-12pm / 2pm-6pm GMT + 1
NOEVIR HOLDINGS CO., LTD. 
